In this article
Viagra Reduces Colorectal Cancer Risk
Scientists report that a small daily dose of Viagra can significantly reduce the risk of colorectal cancer in animal models, which is the third leading cause of cancer death.
Dr. Darren D. Browning, a cancer researcher at the Georgia Cancer Center and the Department of Biochemistry and Molecular Biology, said that Viagra can reduce the formation of polyps in half. Polyps are an abnormal intestinal lining cell cluster and are often asymptomatic, but polyps have The possibility of becoming cancer.
Mechanism of Action and Animal Studies
Viagra can inhibit the naturally occurring enzyme PDE5 in colon cells and other decomposable circulating GMP tissues, so it can be used to reduce cell proliferation and improve cell differentiation, such as goblet cells secreting protective mucus. The study found that targeting circulating GMP signaling seems to be a good prevention strategy for high-risk patients.
The study found that placing Viagra in the drinking water of mice reduced polyps in the mouse model, and the mice had genetic mutations in adenomatous polyposis coli (APC). Like these mice, people with mutations in the APC gene can develop into hundreds or thousands of polyps in the colon and rectum, and ultimately eventually cause colorectal cancer. At the same time, giving Viagra to young mice can reduce the number of tumors in these animals by half.
He pointed out that Viagra has been on the market for many years and is known for its ability to relax smooth muscle cells around blood vessels. It is used in people with multiple doses and age groups, from patients with premature pulmonary hypertension to elderly people with erectile dysfunction. Dr. Browning said that the next step should include clinical trials of drugs in people at high risk for colorectal cancer, such as those with a strong family history, multiple polyps, and chronic intestinal inflammation such as colitis. If the test achieves gratifying results, Viagra will refresh the indications for cancer prevention.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.

About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.
